AXSM - Axsome Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
16.04
+0.10 (+0.63%)
At close: 4:00PM EDT

16.25 +0.21 (1.31%)
After hours: 4:30PM EDT

Stock chart is not supported by your current browser
Previous Close15.94
Open15.98
Bid16.25 x 900
Ask16.40 x 800
Day's Range15.51 - 16.55
52 Week Range1.94 - 16.80
Volume1,147,900
Avg. Volume1,133,416
Market Cap533.818M
Beta (3Y Monthly)3.70
PE Ratio (TTM)N/A
EPS (TTM)-1.15
Earnings DateMay 6, 2019 - May 10, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.60
Trade prices are not sourced from all markets
  • Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal
    Zacks7 days ago

    Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal

    Key highlights of the past week are collaborations and pipeline updates.

  • Axsome's AXS-05 Meets Goal in Phase II Study, Shares Up
    Zacks8 days ago

    Axsome's AXS-05 Meets Goal in Phase II Study, Shares Up

    Axsome's (AXSM) mid-stage candidate, AXS-05, achieves the primary endpoint in a phase II study as a smoking cessation treatment. Shares rise.

  • GlobeNewswire9 days ago

    Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Smoking Cessation

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Duke University has completed its topline analysis of the Phase 2 trial of AXS-05 for smoking cessation treatment. The analysis showed that AXS-05 met the prespecified primary endpoint and significantly reduced daily smoking as compared to the active comparator bupropion. The trial was conducted at the Duke Center for Smoking Cessation under a research collaboration between Axsome and Duke University.

  • Here's Why Axsome Therapeutics Rocketed 78.8% Higher in March
    Motley Fool16 days ago

    Here's Why Axsome Therapeutics Rocketed 78.8% Higher in March

    This tiny biotech may have found the tastiest low-hanging fruit the industry's ever seen.

  • 3 Stocks That Have More Than Tripled So Far in 2019
    Motley Fool17 days ago

    3 Stocks That Have More Than Tripled So Far in 2019

    Can you guess what these high-flying stocks have in common?

  • Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options
    Zacks21 days ago

    Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options

    Investors need to pay close attention to Axsome Therapeutics (AXSM) stock based on the movements in the options market lately.

  • 3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop
    Motley Fool25 days ago

    3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop

    Biogen threw in the towel with once-promising Alzheimer's disease drug aducanumab. But these three late-stage pipeline candidates could potentially still emerge as winners.

  • Axsome's Depression Drug Gets Breakthrough Therapy Status
    Zacks27 days ago

    Axsome's Depression Drug Gets Breakthrough Therapy Status

    Axsome (AXSM) announces that the FDA has granted Breakthrough Therapy designation to AXS-05 for the treatment of major depressive disorder (MDD).

  • 3 Small Biotech Stocks Hitting New Highs
    Investopedia27 days ago

    3 Small Biotech Stocks Hitting New Highs

    Biotech funds have stalled at key retracement levels after strong first quarter bounces and could sell off in the coming weeks, but small biotech stocks are still glued to the top of market performance lists, hitting new highs while posting outsized returns. It's wise to keep one eye on the research calendar when trading small biotech stocks with compounds in the pipeline, hitting the sidelines ahead of key dates because these issues can drop 50% or more overnight after adverse results. New York-based Axsome Therapeutics, Inc. (AXSM) researches and develops compounds and therapies for Alzheimer's disease and other central nervous system disorders.

  • Benzinga27 days ago

    Jim Cramer Weighs In On General Electric, Nio, Sprint And More

    On CNBC's "Mad Money Lightning Round,"  Jim Cramer said SurveyMonkey (NASDAQ: SVMK ) had a fabulous quarter and it should have naver traded lower. Cramer has to do more research on Axsome Therapeutics ...

  • Analysts Are Bullish on Axsome Therapeutics in March
    Market Realist28 days ago

    Analysts Are Bullish on Axsome Therapeutics in March

    How These Biotechnology Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target price Wall Street analysts expect an upside potential of 88.28% for Axsome Therapeutics (AXSM) based on the company’s closing

  • MarketWatch28 days ago

    UPDATE: Axsome Therapeutics shares soar after FDA grants breakthrough designation to depression drug

    Axsome Therapeutics Inc. shares jumped 13% in premarket trade Wednesday, after the U.S. Food and Drug Administration granted breakthrough therapy designation to a treatment for major depressive disorder. The designation, given to the company's AXS-05 oral, investigational NMDA receptor antagonist, gives drug companies an expedited development and review timeline for drugs that are deemed to offer a significant improvement over existing therapies for a serious or life-threatening condition. The decision to award it was based on results from a mid-stage trial that showed a substantial reduction in depressive symptoms. Major depressive disorder affects about 6.7% of U.S. adults and is a chronic, biologically based disorder that can result in suicide. Axsome shares have gained a stunning 468% in the last 12 months, while the S&P 500 has gained 7.9%.

  • GlobeNewswire28 days ago

    Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Major Depressive Disorder

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for AXS-05 for the treatment of major depressive disorder (MDD). AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity.

  • Here's Why Axsome Therapeutics' Stock Gained as Much as 22.9% Today
    Motley Foollast month

    Here's Why Axsome Therapeutics' Stock Gained as Much as 22.9% Today

    Shares have nearly doubled in March following a string of updates, although there was no news on Monday.

  • Have Insiders Been Buying Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares This Year?
    Simply Wall St.last month

    Have Insiders Been Buying Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares This Year?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! We've lost count of how many times insiders have accumulatedRead More...

  • Harry Boxer: 3 biotech stocks with momentum
    MarketWatchlast month

    Harry Boxer: 3 biotech stocks with momentum

    Biotech stocks dominate our list of top charts to watch today. The stock is up over 50% this month, and over 400% since the start of the year, as investors await important clinical trial results on the company’s treatment for depression. Invitae Corp. (NVTA) rose 71 cents to $25.75 on 1.2 million shares Thursday.

  • Associated Presslast month

    Axsome: 4Q Earnings Snapshot

    On a per-share basis, the New York-based company said it had a loss of 32 cents. For the year, the company reported that its loss widened to $31 million, or $1.15 per share. Axsome shares have more than ...

  • GlobeNewswirelast month

    Axsome Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

    Company to host conference call today at 8:00 AM Eastern NEW YORK, March 14, 2019 -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company.

  • 2 Biotech Stocks With Major Incoming Catalysts
    Motley Fool2 months ago

    2 Biotech Stocks With Major Incoming Catalysts

    Clinical trial readouts expected before the end of March will put shares of these drugmakers on the move.

  • GlobeNewswire2 months ago

    Axsome Therapeutics Secures $24 Million Growth Capital Loan Facility Led by Silicon Valley Bank

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has entered into a $24 million growth capital term loan facility with Silicon Valley Bank (SVB) and WestRiver Innovation Lending Fund. Axsome received $20 million at closing, and can draw the remaining $4 million tranche, at its option, subject to the achievement of positive results from the Company’s ongoing Phase 2 trial of AXS-12 in narcolepsy. “Together, these financings extend our cash runway well beyond the data readouts for our five ongoing clinical trials, in five different CNS indications, expected over the next several quarters.

  • GlobeNewswire2 months ago

    Axsome Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for fiscal year 2018 on Thursday, March 14, 2019 before the opening of the U.S. financial markets. AXS-02 is being developed for osteoporosis, the pain of knee osteoarthritis, and chronic low back pain.

  • GlobeNewswire2 months ago

    Axsome Therapeutics Initiates MOMENTUM Phase 3 Trial of AXS-07 in Migraine

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolled the first patient in its MOMENTUM (Maximizing Outcomes in Treating Acute Migraine) study, a Phase 3, randomized, controlled trial assessing the efficacy and safety of AXS-07 (MoSEIC™ meloxicam and rizatriptan) in the acute treatment of migraine. MOMENTUM will enroll only patients with a history of inadequate response to prior migraine treatments.

  • GlobeNewswire3 months ago

    Axsome Therapeutics Receives FDA Agreement under Special Protocol Assessment (SPA) for the MOMENTUM Phase 3 Trial of AXS-07 in Migraine

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has reached agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the design, endpoints, and statistical approach of the planned MOMENTUM (Maximizing Outcomes in Treating Acute Migraine) Phase 3 trial of AXS-07 (MoSEIC™ meloxicam and rizatriptan) in the acute treatment of migraine. MOMENTUM will enroll only patients with a history of inadequate response to prior migraine treatments.

  • GlobeNewswire3 months ago

    Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has initiated the CONCERT (Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment) study, a Phase 2, randomized, controlled trial of AXS-12 (reboxetine) in narcolepsy. AXS-12 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of narcolepsy. Topline results from the CONCERT trial are expected in the second quarter of 2019.

  • 3 Small-Cap Stocks With Big-Cap Potential
    Motley Fool3 months ago

    3 Small-Cap Stocks With Big-Cap Potential

    Sierra Wireless, Innovative Industrial Properties, and Axsome Therapeutics could generate multibagger returns over the long term.